JDJonathan Dick

Jonathan Dick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan Dick has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Standards of diabetes care and burden of hypoglycaemia in people with diabetes on peritoneal dialysis: Results from a real-world clinical audit

    by Piyumi Wijewickrama, Michael Onyema, Hatem Eid, Natalie Phare, Jonathan Dick, Dimitrios Moutzouris, Mark Lambie, Prashant Vas, Jennifer Williams, Janaka Karalliedde

    There is limited data on the standards of diabetes care in people on peritoneal dialysis (PD). Our aim was to assess the standards of diabetes care and the burden of hypoglycaemia in people with diabetes on PD. We performed a retrospective study at three university hospitals from December 2021 to January 2022. Clinical data were extracted from electronic health records. Diabetes care of people on PD was compared against recommended standards for people with diabetes on haemodialysis (as there are no agreed standards for PD). The degree of hypoglycaemia awareness was assessed by validated questionnaires. A total of 65 adults (15 type 1, 49 type 2 and 1 monogenic-diabetes) with a mean age of 63 (range 29–88) years were evaluated. Of them, 92% had diabetes retinal screening with annual review. In contrast, in this high-risk group for foot disease, only 77% had annual foot reviews. The rates of diabetes specialist reviews were variable between hospitals at 63–94% and 10 (15%) had impaired hypoglycaemia awareness. Of the cohort, 32% had HbA1c within the acceptable range of 58–80 mmol/mol (7.5–8.5%), 21% had HbA1c below 58 mmol/mol (7.5%) and 21% ( n = 14) reported at least one hypoglycaemic event per month. Our results indicate variation of care within and between different centres, and the need for improved diabetes care in people on PD. Further work is required to establish agreed standards/recommendations of diabetes care in this population. Our findings highlight the necessity of an integrated multidisciplinary approach to improve the standard of diabetes care for people on PD.


  • Open Access

    Incorporating apolipoprotein L1 testing into evaluation of potential living kidney donors: a single-centre experience

    by Jonathan Dick, Elham Asgari, Paramit Chowdhury, Anita Copley, Isobel Gordon, Rachel Hilton, Christina Horpos, Lisa Silas, Miri Vutabwarova, Refik Gökmen

    Assessment of future risk of end-stage renal disease (ESRD) is an important component of evaluation of potential living kidney donors. Known donor risk factors for ESRD include first-degree relatives, young age, male sex and African descent [1]. In the general population, the presence of two apolipoprotein L1 (APOL1) risk alleles is a key determinant of the excess incidence of ESRD observed in African Americans [2]. In living kidney donors, the effect of the APOL1 genotype on the risk of developing ESRD is unknown. However, the higher risk in black donors and the faster decline in estimated glomerular filtration rate (eGFR) observed post-donation in donors with two APOL1 risk alleles [3] suggests that this group should be considered with caution. The APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) study (NCT03615235) aims to provide prospective data to guide these decisions in the future. In the current absence of prospective data, some centres screen for APOL1 risk alleles in potential donors of African descent. A recent survey of US transplant surgeons and physicians reported that 63% of them intended to use APOL1 testing in the next year [4]. Patient perspectives of APOL1 testing in potential donors are also supportive of this approach [5, 6]. The experience of a policy of testing APOL1 risk alleles in potential donors has not been previously reported.


  • Open Access

    The C3aR promotes macrophage infiltration and regulates ANCA production but does not affect glomerular injury in experimental anti-myeloperoxidase glomerulonephritis

    by Jonathan Dick, Poh-Yi Gan, A Richard Kitching, Stephen R Holdsworth

    The anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides are autoimmune diseases associated with significant morbidity and mortality. They often affect the kidney causing rapidly progressive glomerulonephritis. While signalling by complement anaphylatoxin C5a though the C5a receptor is important in this disease, the role of the anaphylatoxin C3a signalling via the C3a receptor (C3aR) is not known. Using two different murine models of anti-myeloperoxidase (MPO) glomerulonephritis, one mediated by passive transfer of anti-MPO antibodies, the other by cell-mediated immunity, we found that the C3aR did not alter histological disease severity. However, it promoted macrophage recruitment to the inflamed glomerulus and inhibited the generation of MPO-ANCA whilst not influencing T cell autoimmunity. Thus, whilst the C3aR modulates some elements of disease pathogenesis, overall it is not critical in effector responses and glomerular injury caused by autoimmunity to MPO.


  • Open Access

    Pathogenic Role for γδ T Cells in Autoimmune Anti-Myeloperoxidase Glomerulonephritis

    by Poh-Yi Gan, Takeshi Fujita, Joshua Daniel Ooi, Maliha Asghar Alikhan, Jonathan Dick, Raymond Shim, Dragana Odobasic, Kim Maree O’sUllivan, Arthur Richard Kitching, Stephen Roger Holdsworth

    Myeloperoxidase (MPO) anti-neutrophil cytoplasmic Ab (ANCA)–associated vasculitis results from autoimmunity to MPO. IL-17A plays a critical role in generating this form of autoimmune injury but its cell of origin is uncertain. We addressed the hypothesis that IL-17A–producing γδ T cells are a nonredundant requisite in the development of MPO autoimmunity and glomerulonephritis (GN). We studied MPO-ANCA GN in wild type, αβ, or γδ T cell–deficient (C57BL/6, βTCR−/−, and δTCR−/− respectively) mice. Both T cell populations played important roles in the generation of autoimmunity to MPO and GN. Humoral autoimmunity was dependent on intact αβ T cells but was unaffected by γδ T cell deletion. Following MPO immunization, activated γδ T cells migrate to draining lymph nodes. Studies in δTCR−/− and transfer of γδ T cells to δTCR−/− mice show that γδ T cells facilitate the generation of anti-MPO autoimmunity and GN. δTCR−/− mice that received IL-17A−/− γδ T cells demonstrate that the development of anti-MPO autoimmunity and GN are dependent on γδ T cell IL-17A production. Finally, transfer of anti-MPO CD4+ T cell clones to naive δTCR−/− and wild type mice with planted glomerular MPO shows that γδ T cells are also necessary for recruitment of anti-MPO αβ CD4+ effector T cells. This study demonstrates that IL-17A produced by γδ T cells plays a critical role in the pathogenesis of MPO-ANCA GN by promoting the development of MPO-specific αβ T cells.